The results of this study therefore show that IM selleck chemical Enzastaurin olanzapine had a small effect on blood pressure. Treatment with olanzapine may result in fatal outcomes due to diabetic ketoacidosis, diabetic coma, etc. because of a marked increase in the glucose level. Consistent with the results of previous research, the results of this study found that IM olanzapine did not result in an increase in the glucose level to the extent seen with IM haloperidol, and suggested that IM olanzapine may have little effect on the glucose level. Most adverse events were rated mild

or moderate. Furthermore, in this study, no serious adverse events such as paralytic ileus, diabetic ketoacidosis, neuroleptic Inhibitors,research,lifescience,medical malignant syndrome or tardive dyskinesia occurred. Limitations This study had a relatively Inhibitors,research,lifescience,medical small sample size and was a short-term study (2 hours). Furthermore it was an open-label and not a double-blind study, so the possibility that bias was introduced to the results cannot be ruled out. There are consequently limits to the conclusions that can be drawn from this study. Since the doses of IM olanzapine and IM haloperidol used in this study were not equivalent, we cannot rule out the possibility that this affected the

study results. Inhibitors,research,lifescience,medical Furthermore, because only those patients who could give informed consent in this study were included, there is a limit to the results of this study. The greatest problem with this study is that the patients received IM olanzapine or IM haloperidol while

being treated concomitantly with antipsychotic Inhibitors,research,lifescience,medical medications, and it is therefore impossible to completely rule out the possibility that the antipsychotic drugs that the patients were receiving affected the results of this study. A double-blind, randomized, controlled study in subjects who are not taking concomitant medication potentially affecting efficacy and safety may be necessary in the future to clarify the differences in efficacy and safety between IM olanzapine, IM haloperidol and other first-generation injectable formulations. Inhibitors,research,lifescience,medical Conclusion This study was a comparative investigation of the clinical efficacy and safety Drug_discovery of IM olanzapine and IM haloperidol in agitated elderly patients. The results of this study suggest the possibility that agitated elderly patients may result in superior efficacy and safety after IM olanzapine without serious adverse events in comparison with IM haloperidol. Footnotes Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Conflict of interest statement: H.S. received honoraria from Janssen, Otsuka and Dainippon Sumitomo. K.G. received a honoraria from Janssen. Y.T. received honoraria from Otsuka. Contributor Information Hidenobu Suzuki, Department of Psychiatry, Dovitinib clinical trial Suzuki Clinic, 3-34-16 Hamadayama, Suginami, Tokyo, 168-0065, Japan.